Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | BLM | P54132 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 3/20 | 0.51 |
| ▸ | CES1 | P23141 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628871 | 0.89 | IDO1 (0.50) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL12798036 | 0.70 | CES1 (0.54) | MALT1MEN1KMT2AKDM4EMAPT | |
| Lapachone SCHEMBL107042 | 0.68 | MALT1 (1.00) | MALT1MEN1KMT2AKDM4EMAPT | |
| Lapachone SCHEMBL29351050 | 0.68 | MALT1 (1.00) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL25704203 | 0.66 | MEN1 (0.39) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL414700 | 0.65 | S100A4 (0.50) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5940409 | 0.64 | MALT1 (0.69) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5940238 | 0.63 | MAPT (0.40) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5940330 | 0.62 | MALT1 (0.67) | MALT1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL4657699 | 0.61 | S100A4 (0.67) | MEN1KMT2AKDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545507-A4 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | claimed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | KT&G LIFE SCIENCES CORPORATION (KR) | 2012-11-15 | — | — | US | disclosed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050054018-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040266857-A1 | Novel lapachone compounds and methods of use thereof | HINES GLOBAL EDUCATION | 2004-12-30 | — | — | US | disclosed |
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | disclosed |
| WO-2004045557-A2 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | MALT1 980/4885MEN1 4413/4885KMT2A 2159/4885 |
| US-20040266857-A1 | Novel lapachone compounds and methods of use thereof | XIAP, MKI67, PIN1 | MALT1 598/4885MEN1 2813/4885KMT2A 3488/4885 |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | MALT1 3646/4885MEN1 1424/4885KMT2A 4276/4885 |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | MALT1 980/4885MEN1 4413/4885KMT2A 2159/4885 |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | NQO1, MT-ND6, MT-ND5 | MALT1 4836/4885MEN1 373/4885KMT2A 2860/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | MALT1 3696/4885MEN1 1409/4885KMT2A 3411/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | MALT1 3298/4885MEN1 2796/4885KMT2A 4646/4885 |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | MALT1 980/4885MEN1 4413/4885KMT2A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.